Veru (NASDAQ:VERU) Now Covered by Analysts at Westpark Capital

Research analysts at Westpark Capital began coverage on shares of Veru (NASDAQ:VERU) in a research note issued on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating on the stock.

Several other research firms have also recently weighed in on VERU. Wall Street Zen cut Veru from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Weiss Ratings raised Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Veru has a consensus rating of “Moderate Buy” and an average price target of $24.50.

Veru Trading Up 1.4%

Veru stock traded up $0.04 during trading on Tuesday, hitting $2.51. 83,404 shares of the company were exchanged, compared to its average volume of 733,165. The business’s 50 day moving average is $2.54 and its 200 day moving average is $2.53. Veru has a 52 week low of $2.05 and a 52 week high of $7.33. The company has a market capitalization of $42.71 million, a P/E ratio of -3.63 and a beta of -1.21.

Veru (NASDAQ:VERU) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.02. Equities analysts expect that Veru will post -1.07 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of VERU. FNY Investment Advisers LLC purchased a new position in shares of Veru during the 2nd quarter valued at $328,000. Royal Bank of Canada lifted its position in shares of Veru by 69.3% during the 1st quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock valued at $27,000 after buying an additional 5,008 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Veru during the 1st quarter valued at $153,000. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity, oncology and related conditions. The company’s research programs are designed to address cancer-related muscle loss and treatment challenges, as well as the loss of lean muscle that can accompany significant weight reduction.

Veru’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function.